Authors
Meng Li, Ying Li, Xiangyu Wu, Xueting Li, Heli Gao, Xiang Zhong, Xiaohu Yang, Hao Fei, Chunyan Li, Qiangbin Wang
Published in
Biomaterials science. Aug 17, 2026. Epub Aug 17, 2026.
Abstract
Immunotherapy has shown enormous promise for cancer treatment, yet its efficacy is often hindered by the highly immunosuppressive tumor microenvironment (TME). Here, we developed a pH-responsive and cRGD-modified multifunctional liposomal system (FP2@PSLR) to co-deliver an immunogenic cytotoxic peptide (FR) and the PI3Kγ inhibitor IPI549 for coordinated TME remodeling. FR induces immunogenic cell death while exerting direct cytolytic activity, whereas IPI549 promotes macrophage repolarization toward the pro-inflammatory M1-like phenotype, enabling synergistic relief of immune suppression. FP2@PSLR, constructed from acid-sensitive lipids via reverse-phase evaporation, exhibited a uniform size (∼156 nm), high encapsulation efficiencies, excellent physiological stability, and rapid drug release under mildly acidic conditions. In vitro, the liposomes showed good biocompatibility, reduced hemolysis, effective immunogenic cell death induction, dendritic cell activation, and macrophage repolarization. In a 4T1 tumor model, FP2@PSLR demonstrated prolonged circulation, strong αvβ3 integrin-mediated tumor targeting, and clear NIR-II fluorescence for real-time tracking. Treatment resulted in significant TME reprogramming, including enhanced CD8+ T-cell infiltration, increased immune memory formation, and potent antitumor effects without systemic toxicity. These findings highlight FP2@PSLR as a rationally engineered nanoplatform capable of enhancing antitumor immunity through multi-pathway modulation of the immunosuppressive TME.
PMID:
42605855
Bibliographic data and abstract were imported from PubMed on 17 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0